Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTCNASDAQ:CMPSNASDAQ:GALTNASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$13.90+1.8%$13.00$5.74▼$16.90$325.97M0.7641,396 shs33,775 shsCMPSCOMPASS Pathways$3.99+0.3%$3.38$2.49▼$9.63$369.77M2.34792,694 shs1.48 million shsGALTGalectin Therapeutics$1.42+6.0%$1.47$0.73▼$3.78$89.72M0.79316,949 shs133,990 shsOLMAOlema Pharmaceuticals$5.10+1.8%$4.20$2.86▼$16.62$348.50M2.11.06 million shs744,853 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma-0.87%+0.07%-4.74%+27.43%+99.13%CMPSCOMPASS Pathways+10.78%+32.27%+27.17%+2.20%-52.06%GALTGalectin Therapeutics+1.65%-1.31%-18.06%+9.92%-60.00%OLMAOlema Pharmaceuticals+1.71%+18.43%+16.78%-13.76%-49.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.4854 of 5 stars3.62.00.00.03.52.50.0CMPSCOMPASS Pathways2.3009 of 5 stars3.53.00.00.02.70.80.6GALTGalectin Therapeutics0.911 of 5 stars3.01.00.00.00.61.70.0OLMAOlema Pharmaceuticals2.7177 of 5 stars3.53.00.00.03.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 3.22Buy$24.7177.80% UpsideCMPSCOMPASS Pathways 3.00Buy$20.20406.27% UpsideGALTGalectin Therapeutics 2.00Hold$11.00674.65% UpsideOLMAOlema Pharmaceuticals 3.00Buy$27.67442.48% UpsideCurrent Analyst Ratings BreakdownLatest GALT, OLMA, BNTC, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.004/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/28/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/28/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.003/24/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/19/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $25.003/19/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/11/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/5/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.002/28/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.00(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K4,074.61N/AN/A$3.24 per share4.29CMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.01) per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%5/12/2025 (Estimated)CMPSCOMPASS Pathways-$118.46M-$2.30N/AN/AN/AN/A-63.85%-51.97%5/6/2025 (Estimated)GALTGalectin Therapeutics-$41.07M-$0.76N/AN/AN/AN/AN/A-163.15%5/21/2025 (Estimated)OLMAOlema Pharmaceuticals-$96.65M-$2.21N/AN/AN/AN/A-53.56%-47.86%5/6/2025 (Estimated)Latest GALT, OLMA, BNTC, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025GALTGalectin Therapeutics-$0.20N/AN/AN/AN/AN/A5/14/2025Q1 2025CMPSCOMPASS Pathways-$0.47N/AN/AN/AN/AN/A5/14/2025Q1 2025OLMAOlema Pharmaceuticals-$0.52N/AN/AN/AN/AN/A5/12/2025N/ABNTCBenitec Biopharma-$0.36N/AN/AN/AN/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/A3/18/2025Q4 2024OLMAOlema Pharmaceuticals-$0.63-$0.51+$0.12-$0.51N/AN/A2/27/2025Q4 2024CMPSCOMPASS Pathways-$0.62-$0.63-$0.01-$0.63N/AN/A2/14/2025Q2 2025BNTCBenitec Biopharma-$0.55-$0.36+$0.19-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec BiopharmaN/A25.4815.01CMPSCOMPASS Pathways0.158.918.91GALTGalectin TherapeuticsN/A1.131.13OLMAOlema PharmaceuticalsN/A7.107.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%CMPSCOMPASS Pathways46.19%GALTGalectin Therapeutics11.68%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%CMPSCOMPASS Pathways4.25%GALTGalectin Therapeutics50.10%OLMAOlema Pharmaceuticals19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2023.45 million23.15 millionNo DataCMPSCOMPASS Pathways12092.67 million65.51 millionOptionableGALTGalectin Therapeutics963.18 million31.32 millionOptionableOLMAOlema Pharmaceuticals7068.33 million46.18 millionOptionableGALT, OLMA, BNTC, and CMPS HeadlinesRecent News About These CompaniesWall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a BetApril 24 at 10:55 AM | zacks.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Silverarc Capital Management LLCApril 24 at 7:36 AM | marketbeat.com1,651,982 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Purchased by Avoro Capital Advisors LLCApril 23 at 7:22 AM | marketbeat.comBain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 23 at 6:54 AM | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest UpdateApril 21 at 9:51 AM | marketbeat.comAlliancebernstein L.P. Has $1.83 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 20, 2025 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 20, 2025 | marketbeat.comFranklin Resources Inc. Buys 258,625 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 16, 2025 | marketbeat.comWellington Management Group LLP Has $8.84 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 12, 2025 | marketbeat.comAfter Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)April 10, 2025 | zacks.comOlema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable MarketApril 8, 2025 | seekingalpha.comSchroder Investment Management Group Grows Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 7, 2025 | marketbeat.comPictet Asset Management Holding SA Boosts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)April 4, 2025 | marketbeat.comWhy Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 11.17%April 2, 2025 | aaii.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comHighTower Advisors LLC Takes $510,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)March 31, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00March 29, 2025 | marketbeat.comOlema Oncology price target lowered to $28 from $30 at JPMorganMarch 28, 2025 | markets.businessinsider.comPier Capital LLC Invests $1.59 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)March 26, 2025 | marketbeat.comOlema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual MeetingMarch 25, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Olema Pharmaceuticals (OLMA) and Privia Health Group (PRVA)March 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, OLMA, BNTC, and CMPS Company DescriptionsBenitec Biopharma NASDAQ:BNTC$13.90 +0.24 (+1.76%) As of 04:00 PM EasternBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.COMPASS Pathways NASDAQ:CMPS$3.99 +0.01 (+0.25%) As of 04:00 PM EasternCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Galectin Therapeutics NASDAQ:GALT$1.42 +0.08 (+5.97%) As of 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Olema Pharmaceuticals NASDAQ:OLMA$5.10 +0.09 (+1.80%) As of 04:00 PM EasternOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
